598 related articles for article (PubMed ID: 28126188)
21. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Konecny GE
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
[TBL] [Abstract][Full Text] [Related]
22. Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?
El Rassy E; Bakouny Z; Assi T; Kattan J
Future Oncol; 2018 Apr; 14(9):891-895. PubMed ID: 29527939
[TBL] [Abstract][Full Text] [Related]
23. Targeting CDK4/6 pathways and beyond in breast cancer.
Ribnikar D; Volovat SR; Cardoso F
Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
[TBL] [Abstract][Full Text] [Related]
24. [Targeting the cyclin-dependent kinases 4/6 in advanced breast cancers].
Coussy F; Deluche E; Pistilli B; Ladoire S; Ferrero JM; Cottu P
Bull Cancer; 2021 Sep; 108(9):843-854. PubMed ID: 34154797
[TBL] [Abstract][Full Text] [Related]
25. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
[TBL] [Abstract][Full Text] [Related]
26. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
27. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
28. Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value.
Niraula S
Breast; 2019 Feb; 43():81-84. PubMed ID: 30513476
[TBL] [Abstract][Full Text] [Related]
29. Ribociclib (Kisqali) for advanced or metastatic breast cancer.
Med Lett Drugs Ther; 2017 Oct; 59(1532):e178-e179. PubMed ID: 29039822
[No Abstract] [Full Text] [Related]
30. Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.
Med Lett Drugs Ther; 2017 Nov; 59(1533):185-186. PubMed ID: 29125595
[No Abstract] [Full Text] [Related]
31. Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.
Petrelli F; Ghidini A; Pedersini R; Cabiddu M; Borgonovo K; Parati MC; Ghilardi M; Amoroso V; Berruti A; Barni S
Breast Cancer Res Treat; 2019 Apr; 174(3):597-604. PubMed ID: 30659432
[TBL] [Abstract][Full Text] [Related]
32. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
33. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
Sammons SL; Topping DL; Blackwell KL
Curr Cancer Drug Targets; 2017; 17(7):637-649. PubMed ID: 28359238
[TBL] [Abstract][Full Text] [Related]
34. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN; Cristofanilli M
Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
[TBL] [Abstract][Full Text] [Related]
35. CDK4/6 blockade in breast cancer: current experience and future perspectives.
Zardavas D; Pondé N; Tryfonidis K
Expert Opin Investig Drugs; 2017 Dec; 26(12):1357-1372. PubMed ID: 29027483
[TBL] [Abstract][Full Text] [Related]
36. Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
López-Tarruella S; Jerez Y; Márquez-Rodas I; Echavarria I; Martin M
Future Oncol; 2017 Oct; 13(24):2137-2149. PubMed ID: 28758424
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.
Mayer EL
Clin Adv Hematol Oncol; 2015 Apr; 13(4):215-7. PubMed ID: 26352578
[No Abstract] [Full Text] [Related]
38. Treating cancer with selective CDK4/6 inhibitors.
O'Leary B; Finn RS; Turner NC
Nat Rev Clin Oncol; 2016 Jul; 13(7):417-30. PubMed ID: 27030077
[TBL] [Abstract][Full Text] [Related]
39. Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment.
Li J; Jiang J; Wu J; Bao X; Sanai N
Clin Pharmacol Ther; 2021 Feb; 109(2):494-506. PubMed ID: 32799335
[TBL] [Abstract][Full Text] [Related]
40. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.
Corona SP; Generali D
Drug Des Devel Ther; 2018; 12():321-330. PubMed ID: 29497278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]